Pharma’s Take On The Pelosi Drug-Pricing Bill: Fair Warning Or Fearmongering?
The pharmaceutical industry’s argument that capping drug prices would compromise drug innovation stands “on very shaky ground.”
The independent source for health policy research, polling, and news.
981 - 1,000 of 1,592 Results
The pharmaceutical industry’s argument that capping drug prices would compromise drug innovation stands “on very shaky ground.”
President Donald Trump, dogged by an impeachment inquiry, tries to change the subject by unveiling an executive order aimed at expanding the role of private Medicare health plans. The Trump administration also launched an effort this week to expand “wellness” programs aimed at getting people with insurance to practice better health habits – even though research has shown the efforts don’t generally improve health or save money. This week, Alice Miranda Ollstein of Politico, Kimberly Leonard of the Washington Examiner and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.
The topic, which polls show is top of mind among voters, kept returning throughout the fourth debate of Democratic presidential candidates.
Get our weekly newsletter, The Week in Brief, featuring a roundup of our original coverage, Fridays at 2 p.m. ET.
Washington is abuzz with impeachment talk, but what impact would such a move have on congressional action on prescription drug prices and surprise bills? Also, a study out this week shows that health insurance costs for both employers and workers continue to rise. This week, Joanne Kenen of Politico, Paige Winfield Cunningham of The Washington Post and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
Pharmaceutical companies raised the wholesale cost of their drugs by a median of nearly 26% from 2017 to early 2019, according to California’s first-ever report stemming from a new drug price transparency law. Prices for generic drugs rose nearly 38% during that time.
Nearly 8 in 10 Americans say the cost of prescription drugs is unreasonable, but the odds look grim for Congress to pass significant pricing legislation this year.
A lawsuit against Group Health surfaces as the White House promotes Medicare Advantage for seniors.
The president’s directive, which he said is designed to give beneficiaries more choices in their health care, could lead to higher costs for seniors. Final rules are to be written by the Department of Health and Human Services.
Tennessee wants to convert its Medicaid program to a block grant. But is its plan legal? Meanwhile, Congress continues to struggle with legislation to rein in prescription drug prices and surprise medical bills. This week, Anna Edney of Bloomberg News, Jennifer Haberkorn of the Los Angeles Times and Kimberly Leonard of the Washington Examiner join KHN’s Julie Rovner to discuss these issues and more. Rovner also interviews Dr. Marty Makary, author of the new book “The Price We Pay” about why health care costs so much.
The legal fight over the Trump administration’s new rule barring health clinics that receive federal family planning grants from referring women for abortion services played out before a divided federal appeals court Monday. Here are key takeaways.
Nearly 2 million more Americans were uninsured in 2018 than in the previous year, according to the Census Bureau’s annual report. Plus, the Trump administration announced plans to ban flavored vape liquids, and Congress is back and working to address high prescription drug prices and “surprise” medical bills. This week, Joanne Kenen of Politico, Tami Luhby of CNN and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
Almost 80% of Americans support efforts in Congress to protect patients from bills that come from doctors or hospitals that were outside their insurance network.
The president’s outline of key health policy concerns touched on a variety of hot-button issues from drug prices to immigration.
Colorado officials say they haven’t been able to stand up a program to import drugs from Canada because of drugmaker opposition — and the Biden administration’s inaction.
President Donald Trump keeps promising a new health plan, but so far it’s nowhere to be seen. Meanwhile, Democratic presidential candidate Sen. Bernie Sanders (I-Vt.) is proposing a plan to cancel billions of dollars in medical debt owed by patients. This week, Stephanie Armour of The Wall Street Journal, Alice Miranda Ollstein of Politico and Kimberly Leonard of the Washington Examiner join KHN’s Julie Rovner to discuss these issues and more. Rovner also interviews KHN’s Rachel Bluth about the latest “Bill of the Month” feature. Plus, for “extra credit,” the panelists recommend their favorite health stories of the week.
Census officials said most of the drop in health coverage was related to a 0.7% decline in Medicaid. The number of people with private insurance remained steady.
Francis Collins led the National Institutes of Health for 12 years, under three presidents. During the Biden administration, he added White House science adviser to his long list of roles. Now he runs his own lab on the NIH campus, and his latest book, “The Road to Wisdom: On Truth, Science, Faith, and Trust,” came out in September. In this special holiday episode of KFF Health News’ “What the Health?” Collins joins host and chief Washington correspondent Julie Rovner to discuss health misinformation, the Trump administration’s plans for the NIH, and bringing together a fractured society.
© 2026 KFF